Plaque psoriasis: SKYRIZI (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
Psoriatic arthritis: SKYRIZI alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
Podcast
Podcasts:
References
- SKYRIZI (risankizumab) Summary of Product Characteristics.
- Smith CH, et al. BJD 2020, Published: March 18, 2020. DOI:10.1111/bjd.19039.
- Clinicaltrials.gov NCT03478787. https://clinicaltrials.gov/ct2/show/NCT03478787 (Accessed August 2020).
UK-RISN-210515 Date of Preparation: November 2021